160 Results

People

  1. Aghajanian
    Aghajanian
  2. Lichtman
    Lichtman
  3. Sabbatini
    Sabbatini
  4. Hensley
    Hensley
  5. Spriggs
    Spriggs
  6. Dupont
    Dupont
  7. Barakat
    Barakat
  8. Chi
    Chi
  9. Konner
    Konner
  10. Tew
    Tew

Groups

  1. Department of Medicine (160)
  2. Gynecologic Medicine Service (160)
  3. Solid Tumor Oncology Division (160)
  4. GDMT, Medicine (111)
  5. Gynecology Disease Management Team (111)
  6. Surgery (30)
  7. Epidemiology and Biostatistics (25)
  8. Biostatistics Service (23)
  9. GDMT, Surgery (22)
  10. Center for Pancreatic Cancer Research (13)
  1. "clinical trial"
  2. "Gynecologic Medicine Service"
Formats
  1. Journal Article (160)
Groups
  1. Department of Medicine (160)
  2. Gynecologic Medicine Service (160)
  3. Solid Tumor Oncology Division (160)
  4. GDMT, Medicine (111)
  5. Gynecology Disease Management Team (111)
  6. Surgery (30)

More Groups

People
  1. Carol Aghajanian (49)
  2. Paul Sabbatini (48)
  3. Stuart Lichtman (48)
  4. Martee Hensley (34)
  5. David Spriggs (33)
  6. Jakob Dupont (13)

More People

Years
  1. 2024 (5)
  2. 2023 (8)
  3. 2022 (4)
  4. 2020 (2)
  5. 2018 (3)
  6. 2017 (2)

More Years

Publications
  1. Gynecologic Oncology (34)
  2. The Oncology Report (29)
  3. Journal of Clinical Oncology (25)
  4. Clinical Cancer Research (10)
  5. Oncology (Norwalk) (6)
  6. Community Oncology (4)

More Publications

Publishers
  1. Elsevier Inc. (45)
  2. International Medical News Group LLC (29)
  3. American Society of Clinical Oncology (25)
  4. American Association for Cancer Research (11)
  5. Springer (8)
  6. C M P Medica LLC * The Oncology Group (6)

More Publishers

Results (160)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2)
    Journal Article

    Lumish, M.; Chui, M. H.; Zhou, Q.; Iasonos, A.; Sarasohn, D.; Cohen, S.; Friedman, C.; Grisham, R.; Konner, J.; Kyi, C.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • A phase I dose-escalation study of LY3405105, a covalent inhibitor of cyclin-dependent kinase 7, administered to patients with advanced solid tumors
    Journal Article

    Garralda, E.; Schram, A. M.; Bedard, P. L.; Schwartz, G. K.; Yuen, E.; McNeely, S. C.; Ribeiro, S.; Cunningham, J.; Wang, Y.; Urunuela, A.; more...
    The Oncologist (2024)

    Fulltext@MSK | Save
  • A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies
    Journal Article

    Lin, C. C.; Garralda, E.; Schöffski, P.; Hong, D. S.; Siu, L. L.; Martin, M.; Maur, M.; Hui, R.; Soo, R. A.; Chiu, J.; more...
    OncoImmunology (2024)

    Fulltext@MSK | Save
  • Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial
    Journal Article

    Meric-Bernstam, F.; Makker, V.; Oaknin, A.; Oh, D. Y.; Banerjee, S.; González-Martín, A.; Jung, K. H.; Ługowska, I.; Manso, L.; Manzano, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial
    Journal Article

    Friedman, C. F.; D'Souza, A.; Bello Roufai, D.; Tinker, A. V.; de Miguel, M.; Gambardella, V.; Goldman, J.; Loi, S.; Melisko, M. E.; Oaknin, A.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Tisotumab vedotin in combination with carboplatin, pembrolizumab, or bevacizumab in recurrent or metastatic cervical cancer: Results from the innovaTV 205/GOG-3024/ENGOT-cx8 study
    Journal Article

    Vergote, I.; Van Nieuwenhuysen, E.; O'Cearbhaill, R. E.; Westermann, A.; Lorusso, D.; Ghamande, S.; Collins, D. C.; Banerjee, S.; Mathews, C. A.; Gennigens, C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: Phase 1/2 trial interim results
    Journal Article

    Hassan, R.; Butler, M.; O’Cearbhaill, R. E.; Oh, D. Y.; Johnson, M.; Zikaras, K.; Smalley, M.; Ross, M.; Tanyi, J. L.; Ghafoor, A.; more...
    Nature Medicine (2023)

    Fulltext@MSK | Save
  • Progression-free survival and safety at 3.5 years of follow-up: Results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer
    Journal Article

    González-Martín, A.; Pothuri, B.; Vergote, I.; Graybill, W.; Lorusso, D.; McCormick, C. C.; Freyer, G.; Backes, F.; Heitz, F.; Redondo, A.; more...
    European Journal of Cancer (2023)

    Fulltext@MSK | Save
  • A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG Oncology/Gynecologic Oncology Group study 0283
    Journal Article

    O'Cearbhaill, R. E.; Miller, A.; Soslow, R. A.; Lankes, H. A.; DeLair, D.; Segura, S.; Chavan, S.; Zamarin, D.; DeBernardo, R.; Moore, K.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study
    Journal Article

    Sia, T. Y.; Tew, W. P.; Purdy, C.; Chi, D. S.; Menzin, A. W.; Lovecchio, J. L.; Bookman, M. A.; Cohn, D. E.; Teoh, D. G.; Friedlander, M.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save